MASLD with Sven Francque - Part 2

About this episode

This episode discusses the evolving 2024 MASLD treatment guidelines with a focus on weight-loss targets and various treatment options.

The 2024 MASLD treatment guidelines are already changing. Pradeep Mundre and Professor Sven Francque (Antwerp), guideline co-author, cover weight-loss targets (7% and 10%), resmetirom in F2-F3 fibrosis, semaglutide's positive phase 3 in MASH, plus pioglitazone, bariatric surgery, and liver transplantation in this population.

People in this episode

Host: Pradeep Mundre

Guest: Sven Francque

Topics covered

• MASLD
• treatment guidelines
• weight-loss targets
• fibrosis
• bariatric surgery
• liver transplantation

Keywords

• MASLD
• treatment guidelines
• weight-loss
• resmetirom
• semaglutide
• pioglitazone
• bariatric surgery
• liver transplantation

Mentioned in this episode

Organizations: Antwerp

Products: resmetirom, semaglutide, pioglitazone, bariatric surgery, liver transplantation

More episodes of UEG Podcast

• MASLD with Sven Francque - Part 1 · May 26, 2026 · 25 min
• UEG Online Courses x UEG Podcast: Consequences of proctology surgery (LARS) · May 12, 2026 · 20 min
• EoE with Alex Straumann - Part 2 · April 28, 2026 · 16 min
• EoE with Alex Straumann - Part 1 · April 21, 2026 · 23 min
• IBD malignancy with Hannah Gordon · April 7, 2026 · 43 min
• Nutrition in coeliac disease for a clinician with Cristian Costas · March 17, 2026 · 40 min